Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Morgan Stanley Maintains Overweight on Treace Medical Concepts, Raises Price Target to $28
Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Overweight and raises the price target from $23 to $28.
5 Analysts Have This to Say About Treace Medical Concepts
Within the last quarter, Treace Medical Concepts (NASDAQ:TMCI) has observed the following analyst ratings:
BTIG Maintains Buy on Treace Medical Concepts, Raises Price Target to $28
BTIG analyst Ryan Zimmerman maintains Treace Medical Concepts (NASDAQ:TMCI) with a Buy and raises the price target from $23 to $28.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
4 Analysts Have This to Say About Treace Medical Concepts
Over the past 3 months, 4 analysts have published their opinion on Treace Medical Concepts (NASDAQ:TMCI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Maintains Overweight on Treace Medical Concepts, Lowers Price Target to $22
Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Overweight and lowers the price target from $26 to $22.
Analyst Ratings for Treace Medical Concepts
Within the last quarter, Treace Medical Concepts (NASDAQ:TMCI) has observed the following analyst ratings:
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Treace Medical Concepts Reports Secured New 5-Year, $150M Loan Arrangement With MidCap Financial
Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as